Healing scars: targeting pericytes to treat fibrosis

S. N. Greenhalgh, K. P. Conroy, N. C. Henderson*

*Corresponding author for this work

Research output: Contribution to journalLiterature reviewpeer-review

Abstract

Fibrosis, with resultant loss of organ function, is the endpoint of many diseases. Despite this, no effective anti-fibrotic therapies exist. The myofibroblast is the key cell driving fibrosis but its origins remain controversial. A growing body of work provides strong evidence that the pericyte, a perivascular cell present throughout the microvasculature, is a major myofibroblast precursor in multiple tissues. This review summarizes the principle experimental and clinical evidence underpinning this conclusion and outlines strategies for targeting pericyte transdifferentiation during fibrogenesis. Successful targeting of pro-fibrogenic pericytes has the potential to halt or even reverse fibrosis and thus reduce the enormous worldwide healthcare burden that currently exists as a result of fibrotic disease.

Original languageEnglish
Pages (from-to)3-7
Number of pages5
JournalQJM: An International Journal of Medicine
Volume108
Issue number1
DOIs
Publication statusPublished - 22 Mar 2015

Keywords

  • COLLAGEN-PRODUCING CELLS
  • LIVER FIBROSIS
  • KIDNEY FIBROSIS
  • MESENCHYMAL TRANSITION
  • MYOFIBROBLASTS
  • FIBROBLASTS
  • PHENOTYPE
  • ORIGIN

Fingerprint

Dive into the research topics of 'Healing scars: targeting pericytes to treat fibrosis'. Together they form a unique fingerprint.

Cite this